BR0009176A - Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular - Google Patents
Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granularInfo
- Publication number
- BR0009176A BR0009176A BR0009176-6A BR0009176A BR0009176A BR 0009176 A BR0009176 A BR 0009176A BR 0009176 A BR0009176 A BR 0009176A BR 0009176 A BR0009176 A BR 0009176A
- Authority
- BR
- Brazil
- Prior art keywords
- granular
- formulation
- active agent
- stabilized
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title 2
- 239000002552 dosage form Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 5
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 239000006104 solid solution Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"PARTìCULA GRANULAR, FORMA DE DOSAGEM, MéTODOPARA PREPARAR UMA PARTìCULA GRANULAR, MISTURASECA, E, FORMULAçãO GRANULAR". Uma formulação de umagente farmaceuticamente ativo cristalino moderadamente solúvelem água em que o agente ativo é convertido e estabilizado na suaforma amorfa como uma solução sólida de um veículo normalmentehidrofóbico é descrita. O estado amorfo é estabilizado pelacomposição da formulação, fornecendo vida de prateleira longa dacomposição melhorada. Esta formulação estabilizada tambémfornece solubilidade e biodisponibilidade aumentada do agenteativo. As soluções do agente ativo são estabilizadas pelacomposição, evitando recristalização e precipitação da formacristalina menos solúvel do agente ativo das soluções aquosasdestes.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12591499P | 1999-03-24 | 1999-03-24 | |
US14968099P | 1999-08-19 | 1999-08-19 | |
US09/528,624 US6497905B1 (en) | 1999-03-24 | 2000-03-20 | Aqueous solubility pharmaceutical formulations |
PCT/US2000/007298 WO2000056726A1 (en) | 1999-03-24 | 2000-03-20 | Improved aqueous solubility pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0009176A true BR0009176A (pt) | 2001-12-18 |
Family
ID=26824087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009176-6A Pending BR0009176A (pt) | 1999-03-24 | 2000-03-20 | Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular |
Country Status (14)
Country | Link |
---|---|
US (3) | US6497905B1 (pt) |
EP (1) | EP1163234B1 (pt) |
JP (1) | JP2003531099A (pt) |
CN (1) | CN1156461C (pt) |
AT (1) | ATE307808T1 (pt) |
AU (1) | AU3900300A (pt) |
BR (1) | BR0009176A (pt) |
CA (1) | CA2362728C (pt) |
DE (1) | DE60023465T2 (pt) |
DK (1) | DK1163234T3 (pt) |
ES (1) | ES2251985T3 (pt) |
IL (2) | IL145140A0 (pt) |
TW (1) | TWI245644B (pt) |
WO (1) | WO2000056726A1 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2381453A (en) * | 1999-08-31 | 2003-05-07 | Bradford Particle Design Ltd | Active/polymer coformulations |
AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
AU2002249836B2 (en) * | 2000-12-22 | 2006-12-14 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6663897B2 (en) | 2001-02-06 | 2003-12-16 | Dsm Ip Assets B.V. | Oral itraconazole formulations and methods of making the same |
US8071133B2 (en) * | 2001-08-20 | 2011-12-06 | Stiefel Laboratories, Inc. | Oral dosage forms of water insoluble drugs and methods of making the same |
CN100381070C (zh) * | 2002-01-08 | 2008-04-16 | Can科技公司 | 通过用脂质和疏水性高熔点化合物的混合物包覆而进行的包囊化 |
ZA200502496B (en) | 2002-02-28 | 2005-10-12 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
JP4694207B2 (ja) * | 2002-07-05 | 2011-06-08 | コルジウム ファーマシューティカル, インコーポレイテッド | オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 |
DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
US20040086567A1 (en) * | 2002-10-30 | 2004-05-06 | Pawan Seth | Bioequivalent composition of itraconazole and a hydrophilic polymer |
EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
WO2005004763A1 (en) * | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Diffusion layer modulated solids |
HU227142B1 (en) * | 2003-07-02 | 2010-08-30 | Egis Gyogyszergyar Nyilvanosan | Capsule of improved release containing fluconazole |
AU2004311577A1 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
GB0319797D0 (en) * | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
US7413690B1 (en) | 2003-10-29 | 2008-08-19 | The University Of Mississippi | Process and apparatus for producing spherical pellets using molten solid matrices |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
WO2005108683A1 (en) * | 2004-04-29 | 2005-11-17 | Keystone Retaining Wall Systems, Inc. | Veneers for walls, retaining walls and the like |
US7507823B2 (en) | 2004-05-06 | 2009-03-24 | Bristol-Myers Squibb Company | Process of making aripiprazole particles |
SI1765292T1 (en) | 2004-06-12 | 2018-04-30 | Collegium Pharmaceutical, Inc. | Formulations of medicines to discourage abuse |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
MX2007004973A (es) * | 2004-10-25 | 2007-06-14 | Japan Tobacco Inc | Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion. |
BRPI0613611A2 (pt) * | 2005-07-22 | 2011-01-18 | Myriad Genetics Inc | formulações de alta concentração de fármaco e formas de dosagens |
CN100430055C (zh) * | 2005-11-11 | 2008-11-05 | 天津泰普药品科技发展有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法 |
JP2007308479A (ja) | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 固体分散体製剤 |
EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
GB0818403D0 (en) * | 2008-10-08 | 2008-11-12 | Univ Leuven Kath | Aqueous electrophoretic deposition |
WO2010040648A2 (en) * | 2008-10-06 | 2010-04-15 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Functional layers of biomolecules and living cells, and a novel system to produce such |
MX2011006307A (es) | 2008-12-15 | 2011-10-14 | Banner Pharmacaps Inc | Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua. |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US20110150993A1 (en) * | 2009-12-22 | 2011-06-23 | Fmc Corporation | Fine Particle Croscarmellose and Uses Thereof |
EP2601973A1 (en) * | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
JP2014122328A (ja) * | 2012-11-22 | 2014-07-03 | Shin Etsu Chem Co Ltd | 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法 |
GB201602579D0 (en) * | 2016-02-12 | 2016-03-30 | Mihranyan Albert | New compositions |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
WO2019094688A1 (en) * | 2017-11-10 | 2019-05-16 | Dispersol Technologies, Llc | Improved drug formulations |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US5118799A (en) | 1987-05-12 | 1992-06-02 | Pharmacin Corporation | Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate |
EP0462066A1 (en) | 1990-06-15 | 1991-12-18 | Warner-Lambert Company | Amorphous gemfibrozil |
JP2829794B2 (ja) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | 徐放性経口投与型プラノプロフェン製剤 |
US5208015A (en) | 1991-07-23 | 1993-05-04 | Bristol-Myers Squibb Company | Topical anti-fungal agents having anti-inflammatory activity |
US5200195A (en) * | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
ATE138561T1 (de) | 1992-02-12 | 1996-06-15 | Janssen Cilag S P A | Liposomale itraconazol formulierungen |
PL172358B1 (en) | 1992-03-18 | 1997-09-30 | Janssen Pharmaceutica Nv | Stereoisomeric form of itraconazole or saperconazole and method of obtaining same |
PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
IT1256386B (it) * | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
PH31594A (en) | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2722984B1 (fr) | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
US5976555A (en) | 1994-09-07 | 1999-11-02 | Johnson & Johnson Consumer Products, Inc. | Topical oil-in-water emulsions containing retinoids |
TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
NZ322907A (en) | 1995-11-23 | 1998-12-23 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
US5646151A (en) * | 1996-03-08 | 1997-07-08 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
TR199801225T2 (xx) | 1996-05-20 | 1998-11-23 | Janssen Pharmaceutica N.V. | Geli�tirilmi� biyolojik kullan�l�rl��a sahip antifungal bile�imler. |
US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
RU2218153C2 (ru) | 1997-03-26 | 2003-12-10 | Жансен Фармасетика Н.В. | Драже, имеющее ядро, покрытое противогрибковым средством и полимером |
US5813416A (en) | 1997-04-03 | 1998-09-29 | Rudolph; James M. | File with sanitizing agent |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
KR19990001564A (ko) | 1997-06-16 | 1999-01-15 | 유충식 | 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제 |
-
2000
- 2000-03-20 DK DK00918139T patent/DK1163234T3/da active
- 2000-03-20 ES ES00918139T patent/ES2251985T3/es not_active Expired - Lifetime
- 2000-03-20 WO PCT/US2000/007298 patent/WO2000056726A1/en active IP Right Grant
- 2000-03-20 DE DE60023465T patent/DE60023465T2/de not_active Expired - Fee Related
- 2000-03-20 IL IL14514000A patent/IL145140A0/xx active IP Right Grant
- 2000-03-20 AT AT00918139T patent/ATE307808T1/de not_active IP Right Cessation
- 2000-03-20 EP EP00918139A patent/EP1163234B1/en not_active Expired - Lifetime
- 2000-03-20 CA CA002362728A patent/CA2362728C/en not_active Expired - Fee Related
- 2000-03-20 US US09/528,624 patent/US6497905B1/en not_active Expired - Fee Related
- 2000-03-20 JP JP2000606587A patent/JP2003531099A/ja not_active Ceased
- 2000-03-20 AU AU39003/00A patent/AU3900300A/en not_active Abandoned
- 2000-03-20 CN CNB008053995A patent/CN1156461C/zh not_active Expired - Fee Related
- 2000-03-20 BR BR0009176-6A patent/BR0009176A/pt active Pending
- 2000-05-10 TW TW089105331A patent/TWI245644B/zh not_active IP Right Cessation
-
2001
- 2001-06-21 US US09/886,100 patent/US6379707B2/en not_active Expired - Fee Related
- 2001-06-21 US US09/886,493 patent/US6511681B2/en not_active Expired - Fee Related
- 2001-08-27 IL IL145140A patent/IL145140A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2362728A1 (en) | 2000-09-28 |
CA2362728C (en) | 2009-06-23 |
AU3900300A (en) | 2000-10-09 |
DK1163234T3 (da) | 2006-02-27 |
JP2003531099A (ja) | 2003-10-21 |
DE60023465T2 (de) | 2006-07-20 |
ES2251985T3 (es) | 2006-05-16 |
CN1156461C (zh) | 2004-07-07 |
EP1163234A1 (en) | 2001-12-19 |
US6511681B2 (en) | 2003-01-28 |
US20020012706A1 (en) | 2002-01-31 |
US6497905B1 (en) | 2002-12-24 |
ATE307808T1 (de) | 2005-11-15 |
EP1163234B1 (en) | 2005-10-26 |
IL145140A0 (en) | 2002-06-30 |
IL145140A (en) | 2006-08-20 |
US6379707B2 (en) | 2002-04-30 |
TWI245644B (en) | 2005-12-21 |
US20020037324A1 (en) | 2002-03-28 |
EP1163234A4 (en) | 2003-05-02 |
DE60023465D1 (de) | 2005-12-01 |
WO2000056726A1 (en) | 2000-09-28 |
CN1379768A (zh) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0009176A (pt) | Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular | |
DE60038097D1 (de) | Feste orale dosierungsform enthaltend einen resorptionsverstärker | |
CY1120513T1 (el) | Υψηλης συμπυκνωσης συνθεση μινοξιδιλης | |
WO2004012700A3 (en) | Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release | |
CA2382098A1 (en) | Sustained-release, oral pharmaceutical forms of administration | |
ATE307569T1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
CA2370565A1 (en) | Dermally applicable vitamin d-containing pharmaceutical compositions | |
WO2001095856A3 (en) | Urea derivative useful as an anti-cancer agent and process for preparing same | |
CA2385732A1 (en) | Bicyclic compounds composition and method for stabilizing the same | |
EA200000154A1 (ru) | Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях | |
JP2000159790A5 (pt) | ||
YU59201A (sh) | Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina | |
MXPA02001804A (es) | Composicion para inhalacion que comprende delta-9-tetrahidrocanabinol en un solvente semi-acuoso. | |
CA2380757A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
WO2002009717A1 (fr) | Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif | |
EP1219296A4 (en) | SEBUM PRODUCTION INHIBITORS | |
WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
AU2001287801A1 (en) | Acid-sensitive compounds, preparation and uses thereof | |
ATE344237T1 (de) | Hydroxyacetamidobenzolsulfonamidderivate | |
NZ565548A (en) | Stable anthelmintic veterinary formulations containing naphthalophos | |
EP1149832A4 (en) | BENZAMIDE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM | |
NZ505080A (en) | Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid | |
MY101266A (en) | Pharmaceutical formulations | |
CA2395438A1 (en) | Dry compositions containing hydrophobic amino acid | |
CU23441A3 (es) | Composición agroquímica en suspensión acuosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: R.P. SCHERER TECNOLOGIES, INC (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |